Ekso Bionics Holdings Inc Cash Flow Conversion Efficiency
Ekso Bionics Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Ekso Bionics Holdings Inc (EKSO) has a cash flow conversion efficiency ratio of -0.370x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($5.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ekso Bionics Holdings Inc (2012–2025)
Cash flow conversion efficiency of Ekso Bionics Holdings Inc from 2012 to 2025. This chart illustrates how Ekso Bionics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EKSO live share price for real-time trading data and today's change.
Ekso Bionics Holdings Inc Cash Flow Conversion Ratio Explained
Ekso Bionics Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ekso Bionics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ekso Bionics Holdings Inc ranked by their cash flow conversion efficiency. Also see EKSO stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MACH7 Technologies Ltd
AU:M7T
|
0.073x |
|
Woongjin Thinkbig Co Ltd
KO:095720
|
0.087x |
|
Beforepay Group Ltd
AU:B4P
|
-0.080x |
|
Universal Textile Co Ltd
TW:1445
|
0.037x |
|
OssDsign AB
ST:OSSD
|
-0.050x |
|
Mangalam Organics Limited
NSE:MANORG
|
0.034x |
|
NAXS Nordic Access Buyout Fund AB
ST:NAXS
|
-0.002x |
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IS:KAPLM
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Ekso Bionics Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ekso Bionics Holdings Inc from 2012 to 2025. Review Ekso Bionics Holdings Inc (EKSO) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.03 Million | $-11.80 Million | -1.307x | -68.72% |
| 2024-12-31 | $12.71 Million | $-9.85 Million | -0.775x | +18.97% |
| 2023-12-31 | $12.61 Million | $-12.05 Million | -0.956x | -65.63% |
| 2022-12-31 | $25.44 Million | $-14.69 Million | -0.577x | -92.61% |
| 2021-12-31 | $37.22 Million | $-11.16 Million | -0.300x | +84.82% |
| 2020-12-31 | $4.43 Million | $-8.76 Million | -1.975x | +14.91% |
| 2019-12-31 | $6.80 Million | $-15.77 Million | -2.320x | +71.44% |
| 2018-12-31 | $2.73 Million | $-22.16 Million | -8.125x | -456.59% |
| 2017-12-31 | $21.39 Million | $-31.23 Million | -1.460x | +61.86% |
| 2016-12-31 | $6.53 Million | $-25.00 Million | -3.827x | -84.53% |
| 2015-12-31 | $8.81 Million | $-18.27 Million | -2.074x | -215.12% |
| 2014-12-31 | $22.80 Million | $-15.01 Million | -0.658x | +17.39% |
| 2013-12-31 | $15.05K | $-11.99K | -0.797x | 0.00% |
| 2012-12-31 | $15.05K | $-11.99K | -0.797x | -- |
About Ekso Bionics Holdings Inc
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It … Read more